written on 11.04.2014

PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices


Ever since Gilead's $1,000-per-day hepatitis C pill Sovaldi stormed the market late last year, the company has been under pressure from legislators, insurers, and patient advocacy groups to lower its price. Now, doctors are weighing in on the debate.